Rydex Biotechnology Fund Class H
RYOAX
NASDAQ
| Weiss Ratings | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Fair | |||
| Reward Grade | C | |||
| Risk Index | Fair | |||
| Risk Grade | C | |||
| Company Info | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Provider | Rydex Funds | |||
| Manager/Tenure (Years) | Michael P. Byrum (28), Adrian Bachman (4), Brendan Cain (4), 2 others | |||
| Website | http://www.guggenheiminvestments.com | |||
| Fund Information | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Fund Name | Rydex Biotechnology Fund Class H | |||
| Category | Health | |||
| Sub-Category | Healthcare Sector Equity | |||
| Prospectus Objective | Specialty - Technology | |||
| Inception Date | Apr 01, 1998 | |||
| Open/Closed To New Investors | Open | |||
| Minimum Initial Investment | 2,500.00 | |||
| Minimum Subsequent Investment | -- | |||
| Front End Fee | -- | |||
| Back End Fee | -- | |||
| Dividends and Shares | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Yield | 0.00% | |||
| Dividend | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Yield (Forward) | 0.61% | |||
| Asset Allocation | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash | 0.61% | |||
| Stock | 99.39% | |||
| U.S. Stock | 95.72% | |||
| Non-U.S. Stock | 3.67% | |||
| Bond | 0.00% | |||
| U.S. Bond | 0.00% | |||
| Non-U.S. Bond | 0.00% | |||
| Preferred | 0.00% | |||
| Convertible | 0.00% | |||
| Other Net | 0.00% | |||
| Price History | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 1.85% | |||
| 30-Day Total Return | 3.84% | |||
| 60-Day Total Return | -0.25% | |||
| 90-Day Total Return | 10.23% | |||
| Year to Date Total Return | 29.07% | |||
| 1-Year Total Return | 38.10% | |||
| 2-Year Total Return | 54.80% | |||
| 3-Year Total Return | 90.37% | |||
| 5-Year Total Return | 43.12% | |||
| Price | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Closing Price | -- | |||
| 1-Month Low Price | -- | |||
| 1-Month High Price | -- | |||
| 52-Week Low Price | -- | |||
| 52-Week Low Price (Date) | -- | |||
| 52-Week High Price | -- | |||
| 52-Week High Price (Date) | -- | |||
| NAV | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Nav | $74.76 | |||
| 1-Month Low NAV | $70.36 | |||
| 1-Month High NAV | $76.30 | |||
| 52-Week Low NAV | $55.69 | |||
| 52-Week Low NAV (Date) | Mar 27, 2026 | |||
| 52-Week High NAV | $76.30 | |||
| 52-Week High Price (Date) | Oct 29, 2026 | |||
| Beta / Standard Deviation | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.65 | |||
| Standard Deviation | 17.62 | |||
| Balance Sheet | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Total Assets | 131.59M | |||
| Operating Ratios | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Expense Ratio | 1.63% | |||
| Turnover Ratio | 75.00% | |||
| Performance | RYOAX-NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Last Bull Market Total Return | 37.60% | |||
| Last Bear Market Total Return | -10.29% | |||